Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 368 • 2014 ACR/ARHP Annual Meeting
Serum C1M Level Predicts Disease Progression and Early Treatment Efficacy in Rheumatoid Arthritis
Anne C. Bay-Jensen¹, Anne Sofie Siebuhr², Inger Byrjalsen³, Claus Christiansen³ and Morten Asser Karsdal¹, ¹Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is partly characterized by joint destruction. Personalized health care is needed in RA to enable i) prediction of those patients that…
Abstract Number: 2465 • 2014 ACR/ARHP Annual Meeting
Cyclic Phosphatidic Acid (cPA) Suppresses MMP-3, a Disintegrin and Metalloproteinase with Thrombospondin Motifs(ADAMTS)-4, -5 and Stimulates HAS2 Expression in Inflammatory Rheumatoid Synovial Fibroblasts Induced with IL-1β and/or TNF-α
Ikuko Masuda^1,2, Kodo Okada³, Hisashi Yamanaka⁴ and Shigeki Momohara⁴, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Rheumatology, Jyujyo Takeda Rehabilitation Hospital, Kyoto, Japan, ³SANSHO, Co. Ltd., Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose Cyclic phosphatidic acid (cPA) is one of bioactive lipid, has been implicated as an mediator of various biological effects including i) antiproliferative effect on…
Abstract Number: 1524 • 2014 ACR/ARHP Annual Meeting
Rituximab Done! What’s Next in RA?
Ulrich A. Walker¹, Veronika K. Jaeger¹, Katerina Chatzidionysiou², Merete Lund Hetland^3,4, Ellen Margrethe Hauge^3,4, Karel Pavelka⁵, Dan C. Nordström⁶, Helena Canhao⁷, Matija Tomsic⁸, Ronald van Vollenhoven² and Cem Gabay⁹, ¹Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, ²Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ⁴DANBIO, Center for Rheumatology and Spine Diseases, Glostrup University Hospital, Glostrup, Denmark, Glostrup, Denmark, ⁵Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, Helsinki, Finland, ⁷Rheumatology Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal on behalf of the Rheumatic Diseases Portugal Register, Lisbon, Portugal, ⁸Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, Ljubljana, Slovenia, ⁹University Hospitals of Geneva/SCQM Registry, Geneva, Switzerland, Geneva, Switzerland
Background/Purpose The optimal strategy to use biologics after rituximab (RTX) in RA is unknown. We therefore aimed to evaluate the effectiveness of different biologics after…
Abstract Number: 904 • 2014 ACR/ARHP Annual Meeting
Ultrasound Synovitis Reflects Synovial Inflammation at a Histopathological Level
Nora Ng, Stephen Kelly, Frances Humby, Maria DiCicco, Vidalba Rocher, Rebecca Hands, Michele Bombardieri and Costantino Pitzalis, Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
Background/Purpose: Ultrasound (US) is widely used by rheumatologists to assess inflammatory burden on patients with inflammatory arthritis. Some studies have shown that US measures of…
Abstract Number: 375 • 2014 ACR/ARHP Annual Meeting
Evaluation of RAPID3 with Minimal Joint Count and ACR/EULAR Provisional Remission Definitions As Predictors of Future Good Radiographic + Functional Outcome in a Double-Blind, Phase 3, Randomized Controlled Trial of Tocilizumab
Martin J. Bergman¹, Jeffrey Yourish², Jinglan Pei², Jenny Devenport², William Reiss² and Edward Keystone³, ¹Taylor Hospital, Ridley Park, PA, ²Genentech, South San Francisco, CA, ³University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Based on treat-to-target guidelines, the goal of treatment should be remission. Definitions for remission recommended by the ACR/EULAR task force include joint counts and…
Abstract Number: 2426 • 2014 ACR/ARHP Annual Meeting
Comparison of Patient Self-Reported and Physician Reported Rheumatoid Arthritis Medication Use – Results from the Ontario Best Practices Research Initiative
Binu Jacob¹, Xiuying Li¹, Angela Cesta², Bindee Kuriya³, Edward Keystone⁴ and Claire Bombardier³, ¹University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ²Clinical Decision Making and Health Care, University Health Network, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose Patient self-reported medication histories may be prone to misclassification and recall bias. We aimed to assess the agreement between patient (Pt) and physician (MD)…
Abstract Number: 1534 • 2014 ACR/ARHP Annual Meeting
Disease Severity and Treatment of Rheumatoid Arthritis: A Comparative Study Between Sudan and Sweden
Amir Elshafie¹, Abdalla D Elkhalifa², Thomas Weitoft³, Musa Nur⁴, Elnour Elagib⁵, Mawahib Aledrissy⁶, Sahwa Elbagir⁷ and Johan Rönnelid⁸, ¹Immunology, Genetics and Pathology, MD, MDpath, PhD, Uppsala, Sweden, ²Rheumatology unit, MD, Gävle, Sweden, ³Rheumatology unit, MD, PhD, Gävle, Sweden, ⁴Alribat University Hospital, MD, FRCP, Khartoum, Sudan, ⁵Rheumatology unit, Alribat University Hospital, MD, FRCP, Khartoum, Sudan, ⁶Rheumatology unit, Alribat University Hospital, MD, MD internal Medicine, Khartoum, Sudan, ⁷Immunology, Genetics and Pathology, M, PhD student, Uppsala, Sweden, ⁸Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
Background/Purpose: To perform a comparative study concerning clinical characteristics and treatment between Sudanese and Swedish RA outpatients. Methods: A 286 Sudanese and 542 Swedish RA…
Abstract Number: 839 • 2014 ACR/ARHP Annual Meeting
Cardiovascular Risk with Nsaids in Rheumatoid Arthritis: An Analysis Using Routinely Collected Data
Fowzia Ibrahim¹, Antigoni Grigoriou^1,2, Khaldoun Chaabo^1,2, David L. Scott^1,2, Sophia Steer^1,2 and James Galloway^1,2, ¹King's College London, Department of Rheumatology, London, United Kingdom, ²King's College Hospital, Department of Rheumatology, London, London, United Kingdom
Background/Purpose Atherosclerotic disease increases the morbidity and mortality in Rheumatoid Arthritis (RA). NSAIDs are associated with Cardiovascular (CV) risk in the general population. Data from…
Abstract Number: 324 • 2014 ACR/ARHP Annual Meeting
Regulation of TNF-α-Mediated Activation of Rheumatoid Synovial Fibroblasts By Transcription Factor Snail
Chrong-Reen Wang^1,2, Shih-Yao Chen³, Ai-Li Shiau⁴, I-Ming Jou^5,6, Ming-Fei Liu^1,2 and Chao-Liang Wu³, ¹Internal Medicine, National Cheng Kung University Medical College, Tainan, Taiwan, ²Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan, ³Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan, ⁴Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan, ⁵Orthopedics, National Cheng Kung University Medical College, Tainan, Taiwan, ⁶Orthopedics, National Cheng Kung University Hospital, Tainan, Taiwan
Background/Purpose: Transcription factor Snail plays active roles in various biological functions and is involved in many disease states. We hypothesized that this molecule regulates TNF-α-mediated…
Abstract Number: 2686 • 2013 ACR/ARHP Annual Meeting
Impact of Methotrexate Dose Reduction Upon Initiation of Adalimumab On Clinical and Ultrasonographic Parameters in Patients With Moderate to Severe Rheumatoid Arthritis
Gurjit S. Kaeley¹, Amy M. Evangelisto², Midori Jane Nishio³, Shufang Liu⁴ and Hartmut Kupper⁵, ¹College of Medicine, University of Florida, Jacksonville, FL, ²Arthritis, Rheumatic and Back Disease Associates, Voorhees, NJ, ³Diablo Clinical Research, Walnut Creek, CA, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Methotrexate (MTX) is the recommended first-line disease-modifying antirheumatic drug (DMARD) for the treatment of moderately to severely active rheumatoid arthritis (RA). Whether patients (pts)…
Abstract Number: 2242 • 2013 ACR/ARHP Annual Meeting
Patient Versus Physician Joint Counts In Rheumatoid Arthritis Utilizing a Unique Self-Joint Examination Tool
Daisy Bang¹, Yomei Shaw², Christine L. Amity³, Kelly A. Reckley⁴, Ilinca D. Metes⁵ and Marc C. Levesque⁶, ¹Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, ²Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ³Rheumatology & Clinical Immun, Univ of Pittsburgh, Pittsburgh, PA, ⁴Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁵Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The quantitative assessment of disease activity has been endorsed by the American College of Rheumatology (ACR) to improve rheumatoid arthritis (RA) outcomes. To facilitate…
Abstract Number: 1356 • 2013 ACR/ARHP Annual Meeting
Disease Activity Of Rheumatoid Arthritis Is Influenced By Seasonal Change, As Analyzed Based On a Nationwide Japanese Cohort Database
Tetsuji Sawada¹, Hiroaki Mori², Kota Shimada³, Haeru Hayashi¹, Koichiro Tahara¹, Jinju Nishino⁴ and Shigeto Tohma⁵, ¹Rheumatology, Tokyo Medical University, Tokyo, Japan, ²Rheumatology, Tokyo Meidical University, Tokyo, Japan, ³Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁴Nishino Clinic, Orthopedics and Rheumatology, Tokyo, Japan, ⁵Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose: Previous studies have suggested that environmental factors, such as weather, humidity and seasonal change, may affect rheumatoid arthritis (RA). In the present study, we…
Abstract Number: 357 • 2013 ACR/ARHP Annual Meeting
Predictive Value Of Anti Cyclic Citrullinated Peptide and Rheumatoid Factor To The Development Of Rheumatoid Arthritis In a Cohort Of Healthy Relatives Of Patients With Rheumatoid Arthritis
Jose Dionisio Castillo-Ortiz¹ and Cesar Ramos-Remus², ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico
Background/Purpose: Consanguineous relatives of patients with RA are at a higher risk to develop RA. It is also known that specific antibodies including CCP and…
Abstract Number: 2690 • 2013 ACR/ARHP Annual Meeting
Survival Of The Second Biologic After The First Tumor Necrosis Factor Alpha Inhibitor’s Failure In The Treatment Of Rheumatoid Arthritis: Prospective Observational Data From Biorx.Si Registry
ŽIga Rotar¹ and Matija Tomsic², ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia
Background/Purpose: Current recommendations for management of RA propose a tumor necrosis factor alpha inhibitor (TNFi) for patients failing to achieve the treatment target with synthetic…
Abstract Number: 1951 • 2013 ACR/ARHP Annual Meeting
The Spring Ligament Window: A Unique Sonoanatomic View Into a Complex Rheumatoid Joint
Joanne Kitchen¹, I. Moller², Maribel Miguel-Perez³ and David A. Bong⁴, ¹Instituto Poal de Reumatolgia, Barcelona, Spain, ²Instituto Poal, Barcelona, Spain, ³University of Barcelona, Barcelona, Spain, ⁴Instituto Poal de Reumatologia, Barcelona, Spain
Background/Purpose: The calcaneonavicular or spring ligament (SL) is a group of 3 stout non-elastic fibrocartilaginous bands in the medial mid-foot that is important in maintaining…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].